EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety

Hironao Okubo iD, Teppei Matsui, Makoto Chuma, Akihiro Funaoka, Haruki Uojima iD, Satoshi Narahara iD, Masahiro Kobayashi, Yuwa Ando, Tsunamasa Watanabe, Taito Fukushima iD, Satoshi Kobayashi iD, Katsuharu Hirano und 8 weitere

Cancers · 20.08.2026 · 18 (16) · 2703

DOI: 10.3390/cancers18162703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 20.08.2026. Verfasst von Hironao Okubo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima-Ku, Tokyo 177-8521, Japan. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: To investigate early treatment outcomes, including tumor response, predictors of response, and safety of nivolumab plus ipilimumab (Nivo/Ipi) therapy for unresectable hepatocellular carcinoma (uHCC) in a multicenter setting.

Methods

We conducted a retrospective analysis of 64 Japanese patients with uHCC who received Nivo/Ipi therapy at participating centers between July 2025 and April 2026. Treatment efficacy was assessed according to RECIST version 1.1, and adverse events (AEs) were evaluated using CTCAE version 5.0.

Results

Among the 64 patients, 28 received first-line therapy, and 36 received later-line therapy. The median observation period was 5.4 months. The overall response rate (ORR) was significantly higher in the first-line group (60.7%) than in the later-line group (30.6%) (p = 0.016). ORRs according to CRAFITY score were 25.0% for score 0, 55.6% for score 1, and 53.8% for score 2. The ORR in patients with CRAFITY scores ≥ 1 was significantly higher than in patients with a CRAFITY score of 0 (55.0% vs. 25.0%; p = 0.022). Multivariable analysis of pretreatment variables predicting response revealed first-line treatment (OR 3.83, 95% CI 1.270–11.558; p = 0.017) and a CRAFITY score ≥ 1 (OR 4.02, 95% CI 1.232–13.106; p = 0.021) as significant independent factors. Immune-mediated AEs occurred in 70.3% of patients overall and were grade ≥ 3 in 35.9%.

Conclusions

Nivo/Ipi yielded a favorable response when used as first-line therapy. The baseline CRAFITY score may be a useful predictor of response to Nivo/Ipi therapy.

Schlagwörter

Stichwörter der Autor:innen

CRAFITY scoreanti-programmed cell death 1cytotoxic T-lymphocyte-associated protein 4immune-related adverse eventimmunotherapy selectionresponse rate

Autor:innen und Institutionen

  • Department of Gastroenterology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima-Ku, Tokyo 177-8521, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Omorinishi 6-11-1, Ota-Ku, Tokyo 143-8541, Japan.
  • Department of Gastroenterology, Yokohama Hodogaya Central Hospital, 43-1 Kamadai-Cho, Hodogaya-Ku, Yokohama-Shi 240-8585, Japan.
  • Gastroenterological Center, Yokohama City University Medical Center, 4-57, Urafune-Cho, Minami-Ku, Yokohama-Shi 232-0024, Japan.
  • Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto 860-8556, Japan.
  • Gastroenterology Medicine Center, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura-City 247-8533, Japan.

ORCID-Profile: Hironao Okubo, Haruki Uojima, Satoshi Narahara, Taito Fukushima, Satoshi Kobayashi, Kota Tsuruya, Tatehiro Kagawa, Hisashi Hidaka, Yasuhito Tanaka, Shin Maeda

Zitieren

APA

Okubo, H., Matsui, T., Chuma, M., Funaoka, A., Uojima, H., Narahara, S., Kobayashi, M., Ando, Y., Watanabe, T., Fukushima, T., Kobayashi, S., Hirano, K., Tsuruya, K., Kagawa, T., Iwasaki, S., Hidaka, H., Nagai, H., Tanaka, Y., Maeda, S., & Morimoto, M. (2026). Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety. Cancers, 18(16), 2703. https://doi.org/10.3390/cancers18162703

Vancouver

Okubo H, Matsui T, Chuma M, Funaoka A, Uojima H, Narahara S, et al. Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety. Cancers. 2026;18(16):2703. doi:10.3390/cancers18162703

BibTeX
@article{Okubo2026,
  author = {Okubo, Hironao and Matsui, Teppei and Chuma, Makoto and Funaoka, Akihiro and Uojima, Haruki and Narahara, Satoshi and Kobayashi, Masahiro and Ando, Yuwa and Watanabe, Tsunamasa and Fukushima, Taito and Kobayashi, Satoshi and Hirano, Katsuharu and Tsuruya, Kota and Kagawa, Tatehiro and Iwasaki, Shuichiro and Hidaka, Hisashi and Nagai, Hidenari and Tanaka, Yasuhito and Maeda, Shin and Morimoto, Manabu},
  title = {Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2703},
  doi = {10.3390/cancers18162703}
}
Kostenlos starten →